Structure shares up 10.63% intraday after non-exclusive patent license agreement with Roche, securing $100M upfront payment.

martes, 13 de enero de 2026, 10:48 am ET1 min de lectura
GPCR--
Structure surged 10.63% intraday trading, as the company announced a non-exclusive patent licensing agreement with Roche, securing a $100 million upfront payment on December 30, 2025. The company specializes in developing oral small molecule GPCR-targeted therapies, with its lead product Alinaprel for obesity treatment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios